|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
Sep 2019 |
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
Oct 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
The evolving role of next generation sequencing in myelodysplastic syndromes |
Oct 2019 |
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes |
Oct 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency |
Oct 2019 |
The Journal of Clinical Investigation |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
Oct 2019 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
Nov 2019 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Genetic predisposition to MDS: diagnosis and management |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
